Cellular aging and rejuvenation in ischemic heart disease: a translation from basic science to clinical therapy

Abstract

Ischemic heart disease and heart failure (HF) remain the leading causes of death worldwide. The inability of the adult heart to regenerate itself following ischemic injury and subsequent scar formation may explain the poor prognosis in these patients, especially when necrosis is extensive and leads to severe left ventricular dysfunction. Under physiological conditions, the crosstalk between cardiomyocytes and cardiac interstitial/vascular cells plays a pivotal role in cardiac processes by limiting ischemic damage or promoting repair processes, such as angiogenesis, regulation of cardiac metabolism, and the release of soluble paracrine or endocrine factors. Cardiovascular risk factors are the main cause of accelerated senescence of cardiomyocytes and cardiac stromal cells (CSCs), causing the loss of their cardioprotective and repairing functions. CSCs are supportive cells found in the heart. Among these, the pericytes/mural cells have the propensity to differentiate, under appropriate stimuli in vitro, into adipocytes, smooth muscle cells, osteoblasts, and chondroblasts, as well as other cell types. They contribute to normal cardiac function and have an antifibrotic effect after ischemia. Diabetes represents a condition of accelerated senescence. Among the new pharmacological armamentarium with hypoglycemic effect, gliflozins have been shown to reduce the incidence of HF and re-hospitalization, probably through the anti-remodeling and anti-senescent effect on the heart, regardless of diabetes. Therefore, either reducing the senescence of CSC or removing senescent cells from the infarcted heart could represent future antisenescence strategies capable of preventing the deterioration of heart function leading to HF.

Keywords

Aging / ischemic heart disease / rejuvenation / omics / experimental studies

References

[1] Timmis A,Gale C.ESC Scientific Document GroupEuropean society of cardiology: cardiovascular disease statistics 2017.Eur Heart J2018;39:508-79

[2] McDonagh TA,Adamo M.ESC Scientific Document Group2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur Heart J2021;42:3599-726

[3] Argulian E,Shah SJ.Teasing apart heart failure with preserved ejection fraction phenotypes with echocardiographic imaging: potential approach to research and clinical practice.Circ Res2018;122:23-5

[4] Jessup M.Heart failure.N Engl J Med2003;348:2007-18

[5] Steffens S,Madonna R.Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies.Eur Heart J2021:ehab842

[6] Muñoz-Espín D.Cellular senescence: from physiology to pathology.Nat Rev Mol Cell Biol2014;15:482-96

[7] Kuilman T.Senescence-messaging secretome: SMS-ing cellular stress.Nat Rev Cancer2009;9:81-94

[8] Kuilman T,Mooi WJ.The essence of senescence.Genes Dev2010;24:2463-79 PMCID:PMC2975923

[9] Ruiz-Meana M,Ferdinandy P.Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function.Cardiovasc Res2020;116:1835-49

[10] Souders CA,Baudino TA.Cardiac fibroblast: the renaissance cell.Circ Res2009;105:1164-76 PMCID:PMC3345531

[11] Pittenger MF,Beck SC.Multilineage potential of adult human mesenchymal stem cells.Science1999;284:143-7

[12] Olson EN.A decade of discoveries in cardiac biology.Nat Med2004;10:467-74

[13] Reus TL,Da Costa MB,Stimamiglio MA.Secretome from resident cardiac stromal cells stimulates proliferation, cardiomyogenesis and angiogenesis of progenitor cells.Int J Cardiol2016;221:396-403

[14] Madonna R,Kovácsházi C.Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion.J Cell Mol Med2021;25:5381-90 PMCID:PMC8184669

[15] Limana F,Germani A.The epicardium in cardiac repair: from the stem cell view.Pharmacol Ther2011;129:82-96

[16] Forbes SJ.Preparing the ground for tissue regeneration: from mechanism to therapy.Nat Med2014;20:857-69

[17] Mayourian J,Gonzalez DM.Physiologic, pathologic, and therapeutic paracrine modulation of cardiac excitation-contraction coupling.Circ Res2018;122:167-83 PMCID:PMC5886757

[18] Eschenhagen T,Braun T.Cardiomyocyte regeneration: a consensus statement.Circulation2017;136:680-6 PMCID:PMC5557671

[19] Galli D,Staszewsky L.Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells.Arterioscler Thromb Vasc Biol2005;25:692-7

[20] Traktuev DO,Li J.A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks.Circ Res2008;102:77-85

[21] Abel ED,Sweeney G.Cardiac remodeling in obesity.Physiol Rev2008;88:389-419 PMCID:PMC2915933

[22] Sommariva E,Carbucicchio C.Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy.Eur Heart J2016;37:1835-46 PMCID:PMC4912024

[23] Stadiotti I,Vavassori C.Human cardiac mesenchymal stromal cells from right and left ventricles display differences in number, function, and transcriptomic profile.Front Physiol2020;11:604 PMCID:PMC7327120

[24] Amendola A,Songia P.Human cardiosphere-derived stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression.Cardiovasc Res2021;117:1557-66 PMCID:PMC7989620

[25] Rotini A,Duelen R.Aging affects the in vivo regenerative potential of human mesoangioblasts.Aging Cell2018;17:e12714 PMCID:PMC5847873

[26] Perkisas S.Where frailty meets diabetes.Diabetes Metab Res Rev2016;32 Suppl 1:261-7

[27] Palmer AK,LeBrasseur NK,Xu M.Cellular senescence in type 2 diabetes: a therapeutic opportunity.Diabetes2015;64:2289-98 PMCID:PMC4477358

[28] Sloth AD,Munk K.CONDI InvestigatorsImpact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial.BMJ Open2015;5:e006923 PMCID:PMC4390720

[29] Persson F,Jørgensen ME.Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study.Diabetes Obes Metab2018;20:344-51 PMCID:PMC5811811

[30] Zinman B,Lachin JM.EMPA-REG OUTCOME InvestigatorsEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med2015;373:2117-28

[31] Cahn A,Wiviott SD.Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study.Diabetes Care2020;43:468-75

[32] Leiter LA,de Bruin TW,Sugg J.Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.J Am Geriatr Soc2014;62:1252-62

[33] Madonna R,Minnucci I,Pierdomenico DS.Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.J Cell Mol Med2020;24:12331-40 PMCID:PMC7687009

[34] Maly K,Kampfer S.Critical role of protein kinase C α and calcium in growth factor induced activation of the Na⁺/H⁺ exchanger NHE1.FEBS Letters2002;521:205-10

[35] Katare R,Zentilin L.Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling.Circ Res2011;108:1238-51

[36] Madonna R,Rossi C.Transplantation of telomerase/myocardin-co-expressing mesenchymal cells in the mouse promotes myocardial revascularization and tissue repair.Vascul Pharmacol2020;135:106807

[37] Madonna R,Geng YJ.Transplantation of mesenchymal cells rejuvenated by the overexpression of telomerase and myocardin promotes revascularization and tissue repair in a murine model of hindlimb ischemia.Circ Res2013;113:902-14

[38] Madonna R,Geng YJ.Myocardin a enhances telomerase activities in adipose tissue mesenchymal cells and embryonic stem cells undergoing cardiovascular myogenic differentiation.Stem Cells2008;26:202-11

[39] Madonna R.Vascular rejuvenation: a new therapeutic target?.Eur Heart J2021;42:4370-2

[40] Baker DJ,Durik M.Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan.Nature2016;530:184-9 PMCID:PMC4845101

[41] Childs BG,Wijshake T,Campisi J.Senescent intimal foam cells are deleterious at all stages of atherosclerosis.Science2016;354:472-7 PMCID:PMC5112585

[42] Balistreri CR,Ferdinandy P.Is it the time of seno-therapeutics application in cardiovascular pathological conditions related to ageing?.Curr Res Pharmacol Drug Discov2021;2:100027 PMCID:PMC8663954

[43] Gale CP,Woolston A.Resolving inequalities in care?.Eur Heart J2012;33:630-9

[44] Perrino C,Condorelli G.Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart?.Cardiovasc Res2017;113:725-36 PMCID:PMC5437366

[45] Hacker TA,Douglas PS,Aiken JM.Age-related changes in cardiac structure and function in Fischer 344 x Brown Norway hybrid rats.Am J Physiol Heart Circ Physiol2006;290:H304-11

[46] Lesnefsky EJ,Hoppel CL.Mitochondrial metabolism in aging heart.Circ Res2016;118:1593-611 PMCID:PMC5009371

[47] Madonna R,Willerson JT.Biologic function and clinical potential of telomerase and associated proteins in cardiovascular tissue repair and regeneration.Eur Heart J2011;32:1190-6 PMCID:PMC3094547

[48] Cai Y,Song E.Deficiency of telomere-associated repressor activator protein 1 precipitates cardiac aging in mice via p53/PPARα signaling.Theranostics2021;11:4710-27 PMCID:PMC7978321

[49] Liochev SI.Reactive oxygen species and the free radical theory of aging.Free Radic Biol Med2013;60:1-4

[50] Häseli S,Jung T,Ott C.Cardiomyocyte contractility and autophagy in a premature senescence model of cardiac aging.Oxid Med Cell Longev2020;2020:8141307 PMCID:PMC7180990

[51] Moscato S,Bianchi F.Heart and liver connexin expression related to the first stage of aging: a study on naturally aged animals.Acta Histochem2020;122:151651

[52] Ma Y.Metabolic shifts during aging and pathology. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. p. 667-86. PMCID:PMC4968937

[53] Coppé JP,Rodier F.Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.PLoS Biol2008;6:2853-68 PMCID:PMC2592359

[54] Ren J,Zhang Y.Metabolic stress, autophagy, and cardiovascular aging: from pathophysiology to therapeutics.Trends Endocrinol Metab2018;29:699-711 PMCID:PMC6151141

[55] Mouton RE.Ceramide induces expression of the senescence histochemical marker, β-galactosidase, in human fibroblasts.Mech Ageing Dev2000;113:169-81

[56] Tran D,Zhang H.Insulin-like growth factor-1 regulates the SIRT1-p53 pathway in cellular senescence.Aging Cell2014;13:669-78 PMCID:PMC4118446

[57] Kim KS,Baek SH.Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism.Mol Biol Cell2007;18:4543-52 PMCID:PMC2043568

[58] Davalos AR,Malhotra GK.p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes.J Cell Biol2013;201:613-29 PMCID:PMC3653366

[59] Kim CS,Kawada T.Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters.Int J Obes (Lond)2006;30:1347-55

[60] Elzi DJ,Song M,Weintraub ST.Plasminogen activator inhibitor 1--insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence.Proc Natl Acad Sci U S A2012;109:12052-7 PMCID:PMC3409757

[61] Shakeri H,Gevaert AB,Segers VFM.Cellular senescence links aging and diabetes in cardiovascular disease.Am J Physiol Heart Circ Physiol2018;315:H448-62

[62] Zhu Y,Pirtskhalava T.The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.Aging Cell2015;14:644-58 PMCID:PMC4531078

[63] Roos CM,Palmer AK.Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice.Aging Cell2016;15:973-7 PMCID:PMC5013022

[64] Walaszczyk A,Redgrave R.Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction.Aging Cell2019;18:e12945 PMCID:PMC6516151

[65] Guerrero A,Sun B.Cardiac glycosides are broad-spectrum senolytics.Nat Metab2019;1:1074-88 PMCID:PMC6887543

[66] Lazaro I,Recio C.Targeting HSP90 ameliorates nephropathy and atherosclerosis through suppression of NF-κB and STAT signaling pathways in diabetic mice.Diabetes2015;64:3600-13

[67] Mattison JA,Bernier M.Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates.Cell Metab2014;20:183-90 PMCID:PMC4254394

[68] Gao D,Tian J.Activation of SIRT1 attenuates klotho deficiency-induced arterial stiffness and hypertension by enhancing AMP-activated protein kinase activity.Hypertension2016;68:1191-9 PMCID:PMC5063709

[69] Liu Y,Zhang R.Calorie restriction protects against experimental abdominal aortic aneurysms in mice.J Exp Med2016;213:2473-88 PMCID:PMC5068228

[70] Werner C,Pöss J,Böhm M.Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis.Atherosclerosis2011;216:23-34

[71] Walters HE,Cox LS.Reversal of phenotypes of cellular senescence by pan-mTOR inhibition.Aging (Albany NY)2016;8:231-44 PMCID:PMC4789579

[72] Bennaceur K,Al Zhrany N.Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism.Atherosclerosis2014;236:312-20